Coming off a Healthy Pulse - Research Report on Pfizer Inc., Johnson & Johnson, Abbott Laboratories, AstraZeneca plc. and Novartis AG

Tue Feb 19, 2013 8:02am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130219:nPn2194465


NEW YORK,  February 19, 2013  /PRNewswire/ --

Today, National Traders Association announced new research reports for Pfizer
Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ),
AstraZeneca plc. (NYSE: AZN) and Novartis AG (NYSE: NVS). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

Viiv Healthcare Ltd., Pfizer's joint venture with two other drug makers, has
issued a statement that the US Food and Drug Administration (FDA) has granted
priority review status to the experimental HIV medicine dolutegravir. Priority
status can be granted to drugs that offer significant improvement over existing
treatments or to drugs that offer treatment for a disease that does not have any
other type of cure. If the drug is approved, dolutegravir will be the second in
a new type of HIV medicines called integrase inhibitors. Integrase inhibitors
work by blocking the HIV's ability to replicate, therefore blocking the spread
of the virus all over the body. This cutting-edge drug represents an opportunity
for Pfizer to boost its pipeline given the market for HIV patients worldwide.
The Full Research Report on Pfizer Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge at: 
http://www.nationaltradersassociation.org/r/full_research_report/bd2d_PFE

--

Johnson & Johnson Research Report

Janssen Research & Development, Johnson & Johnson's pharmaceutical company, has
announced that the FDA has granted Breakthrough Therapy Designation for the
investigational oral agent ibrutinib. The drug treats patients with B-Cell
malignancies like relapsed or refractory mantle cell lymphoma (MCL) and
Waldenstrom's macroglobulinemia (WM). The Breakthrough Therapy Designation
speeds up the review time for a new type of medicine that can treat a serious or
life-threatening disease or condition. Five thousand new MCL cases are reported
every year, while 1,200 WM cases are reported each year, representing the
potential market for Johnson & Johnson's ibrunitib. The Full Research Report on
Johnson & Johnson - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at: 
http://www.NationalTradersAssociation.org/r/full_research_report/b230_JNJ     

--

Abbott Laboratories Research Report

Abbott has announced its 357th  consecutive quarterly dividend at  14 cents  per
share, payable  May 15, 2013. Earlier this year, Abbott announced that the FDA
has approved its next-generation Xience Xpedition drug eluting stent system.
Xpedition provides physicians with a trusted option to treat a broad range of
patients suffering from coronary artery disease. With this product, physicians
will have a new technology to reach blockage and restore blood flow with ease.
Abbott's Xience line has been the bestselling stent for several years,
generating  $1 billion  yearly for Abbott since 2009. Abbott's next product, the
Absorb stent, is currently in clinical trials in the US and the company plans to
file the product for regulatory approval by 2015. These unique products face
minimal competition, giving Abbott a major share in the treatment of coronary
artery diseases. The Full Research Report on Abbott Laboratories- including full
detailed breakdown, analyst ratings and price targets - is available to download
free of charge at: 
http://www.NationalTradersAssociation.org/r/full_research_report/b8f0_ABT

--

AstraZeneca plc. Research Report

AstraZeneca has announced that it will collaborate with N.N. Petrov Institute of
Oncology, one of  Russia's  leading cancer institutions. Petrov Institute
scientists will work with AstraZeneca's Oncology Innovative Medicines group at
various centers worldwide to evaluate the role that genetic mutations play in
developing cancer. Analysts believe that this collaboration will effectively
boost the company's pipeline. Other efforts by the company to expand and
diversify include collaborating with Isis Pharmaceuticals to develop a new
generation antisense therapeutics against five cancer targets as well as
acquiring Ardea, a biotechnology company with an ongoing gout program that has
the potential to treat millions of patients worldwide. The Full Research Report
on AstraZeneca plc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at: 
http://www.NationalTradersAssociation.org/r/full_research_report/2770_AZN

--

Novartis AG Research Report

Novartis has favorable news to offer its investors. The company issued a
statement saying that the FDA has approved Zortress, the first mTOR inhibitor
drug that prevents organ rejection in adult liver transplant patients in the US,
where it is already approved for kidney transplantation. The drug was also
approved under the name Certican by European Health Authorities in the fourth
quarter of 2012. At present, more than 6,000 liver transplants are performed in 
the United States  each year, representing the potential market for Zortress.
The drug is the first immunosuppressant approved by the FDA in over a decade for
liver transplantation. Novartis' Exjade also received FDA approval earlier this
year. The Full Research Report on Novartis AG - including full detailed
breakdown, analyst ratings and price targets - is available to download free of
charge at: 
http://www.NationalTradersAssociation.org/r/full_research_report/5dc9_NVS

--

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Demi Lapierre

Email:  press@NationalTradersAssociation.org

Main: +1-(702)-212-4493


SOURCE  National Traders Association

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.